AXSOME THERAPEUTICS INC's ticker is AXSM and the CUSIP is 05464T104. A total of 172 filers reported holding AXSOME THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $573,307 | +122.8% | 8,203 | +96.6% | 0.00% | +200.0% |
| Q2 2023 | $257,328 | 0.0% | 4,172 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $257,328 | -49.2% | 4,172 | -36.4% | 0.00% | -66.7% |
| Q4 2022 | $506,127 | -27.1% | 6,562 | -57.8% | 0.00% | -25.0% |
| Q3 2022 | $694,000 | +219.8% | 15,561 | +173.7% | 0.00% | +300.0% |
| Q2 2022 | $217,000 | +3.8% | 5,685 | +2.7% | 0.00% | 0.0% |
| Q4 2021 | $209,000 | -43.7% | 5,535 | +0.6% | 0.00% | -50.0% |
| Q2 2021 | $371,000 | +14.5% | 5,500 | -4.1% | 0.00% | 0.0% |
| Q1 2021 | $324,000 | -29.9% | 5,735 | +1.1% | 0.00% | -33.3% |
| Q4 2020 | $462,000 | +26.9% | 5,675 | +11.0% | 0.00% | +50.0% |
| Q3 2020 | $364,000 | +68.5% | 5,113 | +94.2% | 0.00% | +100.0% |
| Q2 2020 | $216,000 | -59.0% | 2,633 | -48.4% | 0.00% | -50.0% |
| Q1 2020 | $527,000 | 0.0% | 5,106 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $527,000 | +335.5% | 5,106 | -15.0% | 0.00% | +100.0% |
| Q3 2019 | $121,000 | +36.0% | 6,005 | +73.6% | 0.00% | – |
| Q2 2019 | $89,000 | – | 3,460 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ALETHEA CAPITAL MANAGEMENT, LLC | 1,132,645 | $37,332,000 | 32.86% |
| MORGAN JESS S & CO INC | 113,430 | $3,739,000 | 2.47% |
| Fairmount Funds Management LLC | 187,598 | $6,183,000 | 2.25% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 1,423,653 | $46,924,000 | 1.43% |
| WMS Partners, LLC | 250,000 | $8,240,000 | 1.21% |
| Beck Bode, LLC | 102,127 | $3,366,000 | 0.94% |
| RTW INVESTMENTS, LP | 1,616,497 | $53,280,000 | 0.80% |
| MPM BioImpact LLC | 110,155 | $3,631,000 | 0.56% |
| Endurant Capital Management LP | 52,048 | $1,716,000 | 0.39% |
| Bellevue Group AG | 752,945 | $24,817,000 | 0.25% |